GlassScriptPhysician profile
Melody E Sands
NPI 1053397786
$1,510.43
in general payments reported to CMS, 2019-2025
32 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.45 · 2022: $180 · 2023: $387 · 2024: $351 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $197.44 | 2023-2025 | |
| Genzyme Corporation | $142.50 | 2022-2024 | |
| Janssen Biotech, INC. | $85.68 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Array Biopharma INC | $82.70 | 2024-2025 | Braftovi, Xalkori, Mektovi |
| Celgene Corporation | $74.87 | 2023-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $71.95 | 2022-2023 | Keytruda, Reblozyl, Welireg |
| Amgen INC. | $66.94 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $46.79 | 2025 | Lynparza, Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.99 | 2025 | |
| Abbvie INC. | $38.38 | 2023-2025 | |
| Glaxosmithkline, LLC. | $32.15 | 2025 | Zejula, Blenrep |
| Apellis Pharmaceuticals, INC. | $27.47 | 2023 | Empaveli |
| Daiichi Sankyo INC. | $26.73 | 2022 | |
| Jazz Pharmaceuticals INC. | $26.45 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $25.48 | 2025 | |
| Astellas Pharma US INC | $25.18 | 2025 | Padcev |
| Eisai INC. | $24.55 | 2023 | |
| Adaptive Biotechnologies Corporation | $23.59 | 2024 | Clonoseq |
| Kite Pharma, INC. | $22.96 | 2025 | Yescarta |
| Sun Pharmaceutical Industries INC. | $22.15 | 2025 | |
| Morphosys, US INC. | $22.05 | 2021 | |
| Adc Therapeutics America, INC. | $20.69 | 2023 | |
| Cti Biopharma Corp. | $20.67 | 2022 | |
| Seagen INC. | $20.24 | 2022 | |
| Puma Biotechnology, INC. | $19.53 | 2025 | |
| Pharmacosmos Therapeutics INC. | $18.65 | 2023 | Monoferric |
| Genentech USA, INC. | $18.19 | 2024 | Venclexta |
| Novocure INC. | $18.03 | 2024 | Optune Lua (Novottf-200t) |
| Recordati_rare_diseases_inc. | $18.02 | 2025 | Enjaymo |
| Pharmacyclics LLC, An Abbvie Company | $13.46 | 2023 | Epkinly |
| Tersera Therapeutics LLC | $13.20 | 2023 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.